Breaking News, Collaborations & Alliances

Avid Selected to Lead Process Development of IOV-3001

Will provide process development, pilot-batch manufacturing & CGMP manufacturing services for Iovance Biotherapeutics.

By: Contract Pharma

Contract Pharma Staff

Iovance Biotherapeutics has selected Avid Bioservices Inc. to provide process development, pilot-batch manufacturing and CGMP manufacturing services to support development of IOV-3001, a novel antibody cytokine engrafted protein.    Cell line development activities for IOV-3001 are currently being conducted by Aragen Bioscience under a subcontracting agreement with Avid. In parallel with cell line development, Avid will commence analytical activities, upstream and downstream process development,...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters